NEW YORK (TheStreet) -- Shares of Colgate-Palmolive Co  (CL) were retreating, down 1.16% to $66.29 in early market trading Thursday, after analysts at Morgan Stanley downgraded the consumer products giant earlier today.

Colgate-Palmolive had its rating cut to "equal weight" from "overweight" at Morgan Stanley on a valuation call.

Analysts at the firm said valuation now reflects the company's superior fundamentals and leaves little room for upside.

Morgan Stanley also lowered its price target on shares to $72 from $76, citing unfavorable currency pressures and a difficult competitive environment.

Yesterday, Colgate-Palmolive was upgraded by analysts at Societe Generale.

Analysts at Societe Generale raised their rating to "hold" with a higher price target of $68, saying the majority of growth headwinds are beginning to turn.

New York City-based Colgate-Palmolive is a consumer products company with oral care, personal care, home care, and pet nutrition products marketed in more than 200 countries and territories around the world.

Separately, TheStreet Ratings team rates COLGATE-PALMOLIVE CO as a Buy with a ratings score of B. TheStreet Ratings Team has this to say about their recommendation:

"We rate COLGATE-PALMOLIVE CO (CL) a BUY. This is driven by several positive factors, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its increase in net income, notable return on equity, expanding profit margins and growth in earnings per share. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself."

If you liked this article you might like

With Eyes on Solar Eclipse, Wall Street Stumbles Yet Again

Unilever Bankers Said to Be Pushing for Colgate-Palmolive Takeover